Our screening procedure was robust as a subset of the highly ranked genes (BAX, BIM, BAP1, and SPRED2) had previously been correlated to either CML progression, imatinib resistance, or resistance to alternative therapies in different cancer types.24, 34, 35, 36, 37. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.